**Description**

**A COMPOSITION COMPRISING MYOTROPIC COMPONENTS THAT EXHIBIT THE CHARACTERISTIC OF SUPPRESSING MONOAMINE OXIDASE B**

**Technical Field**

The invention relates to a composition comprising myotropic components formed for suppressing monoamine oxidase B.

**State of the Art**

Monoamine oxidases, or MAO, are the enzymes that catalyze the oxidation of the monoamines. This enzyme was first found by Mary Bernheim in the liver cells and was named as “tyramineoxidase". It breaks down the amine neurotransmitters such as dopamine, norepinephrine and serotonin. This protein is present in the mitochondrial external membrane. It is synthesized by the gene monoamine oxidase A, or MAOA. The deficiency of monoamine oxidase causes the Brunner syndrome. It is classified into two types, namely MAO-A and MAO-B. Both are present in the neurons and astroglia. Other than the central nervous system, MAO-A is also present in the liver, digestive system and placenta. MAO-B is present mostly in the blood platelets.

According to the state of the art, the invention no. EP1483247B1 with classification “C07D 239/46” entitled “Aryl substituted pyrimidines and the use thereof” relates to a method of treating disorders responsive to the blockade of sodium ion channels using novel aryl-substituted pyrimidine compounds of Formula (I) or a pharmaceutically acceptable salt, or solvate thereof, wherein A, R1, R2, R3 and R4 are defined in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

As a result, the presence of the need for a composition for suppressing monoamine oxidase B and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

**Object of the Invention**

In order to eliminate the disadvantages of the state of the art, an object of the invention is to enable the suppression of monoamine oxidase B.

Another object of the invention is to enable the triggering of the increase in cAMP.

In order to achieve the aforesaid advantages, the invention is a composition for suppressing monoamine oxidase B, said composition being obtained by the components selected from the group comprising **3,7-bis(2-hydroxyethyl)3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-yl)-4H-1-protospinol-phenyl-taurinate, 3,7-bis(2-hydroxymethyl)3,5-trihydroxy-2-(4-methoxyphenyl)-8-(2-diethyl-2-buten-yl)-2H-1-protospinol** that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

**Detailed Description of the Invention**

The invention is a composition comprising myotropic components formed for suppressing monoamine oxidase B. Said invention enables the suppression of monoamine oxidase B and enables the triggering of the increase in cAMP.

The composition according to the invention contains **3,7-bis(2-hydroxyethyl)3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-yl)-4H-1-protospinol-phenyl-taurinate, 3,7-bis(2-hydroxymethyl)3,5-trihydroxy-2-(4-methoxyphenyl)-8-(2-diethyl-2-buten-yl)-2H-1-protospinol**.

Said composition is obtained by a mixture of the aforesaid components according to the following ratios by weight:

**1-99% 3,7-bis(2-hydroxyethyl)3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-yl)-4H-1-protospinol-phenyl-taurinate,**

**99-1%** **3,7-bis(2-hydroxymethyl)3,5-trihydroxy-2-(4-methoxyphenyl)-8-(2-diethyl-2-buten-yl)-2H-1-protospinol.**

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for suppressing monoamine oxidase B and the manufacture thereof for this purpose.

**CLAIMS**

1. A composition for suppressing monoamine oxidase B, said composition being obtained by the components selected from the group comprising **3,7-bis(2-hydroxyethyl)3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-yl)-4H-1-protospinol-phenyl-taurinate, 3,7-bis(2-hydroxymethyl)3,5-trihydroxy-2-(4-methoxyphenyl)-8-(2-diethyl-2-buten-yl)-2H-1-protospinol** that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 1-99% by weight **3,7-bis(2-hydroxyethyl)3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-yl)-4H-1-protospinol-phenyl-taurinate**.
3. A composition according to Claim 1 characterized in that it comprises 99-1% by weight **3,7-bis(2-hydroxymethyl)3,5-trihydroxy-2-(4-methoxyphenyl)-8-(2-diethyl-2-buten-yl)-2H-1-protospinol**.
4. Use of the components according to Claims 1 to 3 obtained individually or in combinations selected from the group consisting of **3,7-bis(2-hydroxyethyl)3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-yl)-4H-1-protospinol-phenyl-taurinate, 3,7-bis(2-hydroxymethyl)3,5-trihydroxy-2-(4-methoxyphenyl)-8-(2-diethyl-2-buten-yl)-2H-1-protospinol** for the manufacture of a composition for suppressing monoamine oxidase B.

**ABSTRACT**

**A COMPOSITION COMPRISING MYOTROPIC COMPONENTS THAT EXHIBIT THE CHARACTERISTIC OF SUPPRESSING MONOAMINE OXIDASE B**

The invention relates to a composition comprising myotropic components formed for suppressing monoamine oxidase B.

No figure.